Last updated on December 2018

Evaluating the Safety and Efficacy of Fecal Microbiota Transplant in Peanut Allergic Patients


Brief description of study

This is a Phase I trial to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in the treatment of peanut allergy. In this research the investigators would like to learn more about ways to treat peanut allergies. There is currently no known cure for peanut allergy. The primary aim is to assess safety and tolerability of oral FMT in patients with peanut allergy aged 18-40 years.

Detailed Study Description

This is a study of fecal microbiota transplantation (FMT) in the treatment of peanut allergy. The primary aim is to assess safety and tolerability of oral FMT in patients with peanut allergy aged 18-40 years. A total of 10 patients with peanut allergy will be enrolled after they fail a screening food challenge to peanut. Participating will be given oral encapsulated frozen FMT over 2 days. Patients will undergo a second and third food challenge after receiving FMT. The expected duration of the study for each subject will be one year. Stool collection, skin testing and blood samples will be done serially.

Clinical Study Identifier: NCT02960074

Contact Investigators or Research Sites near you

Start Over

Rima Rachid, MD

Boston Children's Hospital
Boston, MA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.